Bin Qi

Dr. Bin Qi

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2021 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
LMLiu Miao
Liu Miao
YMYan Min
Yan Min
BQBin Qi
Bin Qi
CZChuan-Meng Zhu
Chuan-Meng Zhu
JCJian-Hong Chen
Jian-Hong Chen
RLRong-Shan Li
Rong-Shan Li
Background: While observational studies show an association between serum lipid levels and cardiovascular disease (CVD), intervention studies that examine the preventive effects of serum lipid levels on the development of CKD are lacking. Methods: To estimate the role of serum lipid levels in the etiology of CKD, we conducted a two-sample mendelian randomization (MR) study on serum lipid levels. Single nucleotide polymorphisms (SNPs), which were significantly associated genome-wide with serum lipid levels from the GLGC and CKDGen consortium genome-wide association study (GWAS), including total cholesterol (TC, n = 187,365), triglyceride (TG, n = 177,861), HDL cholesterol (HDL-C, n = 187,167), LDL cholesterol (LDL-C, n = 173,082), apolipoprotein A1 (ApoA1, n = 20,687), apolipoprotein B (ApoB, n = 20,690) and CKD (n = 117,165), were used as instrumental variables. None of the lipid-related SNPs was associated with CKD (all P > 0.05). Results: MR analysis genetically predicted the causal effect between TC/HDL-C and CKD. The odds ratio (OR) and 95% confidence interval (CI) of TC within CKD was 0.756 (0.579 to 0.933) (P = 0.002), and HDL-C was 0.85 (0.687 to 1.012) (P = 0.049). No causal effects between TG, LDL-C- ApoA1, ApoB and CKD were observed. Sensitivity analyses confirmed that TC and HDL-C were significantly associated with CKD. Conclusions: The findings from this MR study indicate causal effects between TC, HDL-C and CKD. Decreased TC and elevated HDL-C may reduce the incidence of CKD but need to be further confirmed by using a genetic and environmental approach.

Verified
Journal Article
Open access
PDF file
BQBin Qi
Bin Qi
ZYZhi-Jie Yang
Zhi-Jie Yang
NHNan Huang
Nan Huang
WZWen-Bo Zheng
Wen-Bo Zheng
CGChun Gui
Chun Gui
Objective: Little is known about gut microbiota (GM) and cardiomyopathy. Their causal relationship was explored using two-sample Mendelian randomization (TSMR) performed by R software. Methods: The single nucleotide polymorphisms (SNPs) were further screened based on the genome-wide association studies (GWAS) of gut microbiota and cardiomyopathy obtained from an open database. TSMR was performed using an MR-Egger regression, simple estimator based on mode, weighted median method, inverse variance weighted (IVW), weighted estimator and CML-MA-BIC to explore the causal association. And the sensitivity analysis was carried out using an MR-Egger regression and the leave-one-out sensitivity test. Results: As for 211 GM taxa, IVW results confirmed that the class Actinobacteria (OR = 0.81, p = 0.021) and genus Coprobacter (OR = 0.85, p = 0.033) were protective factors for cardiomyopathy. The phylum Firmicutes (OR = 0.87, p < 0.01), family Acidaminococcaceae (OR = 0.89, p < 0.01), genus Desulfovibrio (OR = 0.92, p = 0.030) and genus Prevotella9 (OR = 0.93, p = 0.029) were protective factors for ischemic cardiomyopathy. The family Rhodospirillaceae (OR = 1.06, p = 0.036) and genus Turicibacter (OR = 1.09, p = 0.019) were risk factors for ischemic cardiomyopathy. The genus Olsenella (OR = 0.91, p = 0.032) was a protective factor for non-ischemic cardiomyopathy. The order Rhodospirillales (OR = 1.14, p = 0.024), family Rikenellaceae (OR = 1.21, p = 0.012) and genus Gordonibacter (OR = 1.12, p = 0.019) were risk factors for non-ischemic cardiomyopathy. The robustness of MR results was reflected in the heterogeneity (p > 0.05) and pleiotropy (p > 0.05) analyses. Conclusions: A potential causal relationship of cardiomyopathy with some GM taxa has been confirmed in the current study.

3 November 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
BQBin Qi
Bin Qi
YLYong-Fa Lei
Yong-Fa Lei
WWW. U.-Qi Wei
W. U.-Qi Wei
WZWen-Bo Zheng
Wen-Bo Zheng
Introduction: Percutaneous coronary intervention (PCI) necessitates efficient periprocedural anticoagulation. Although traditional heparin-based protocols have been the norm, apprehensions about bleeding risk and variable responses remain. Bivalirudin, a direct thrombin inhibitor, presents a potential alternative; nonetheless, its relative efficacy and safety compared to heparin remain ambiguous due to inconsistent findings from previous trials and meta-analyses. This systematic review and meta-analysis seeks to offer a modern synthesis comparing bivalirudin with traditional anticoagulation in patients having percutaneous coronary intervention (PCI). Materials and Methods: We performed a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Assessment of Multiple Systematic Reviews (AMSTAR) standards. A thorough search of PubMed, Embase, Cochrane Library, and Web of Science from inception to 15 December 2025, identified randomised controlled trials (RCTs) comparing bivalirudin versus heparin-based regimens (with or without glycoprotein IIb/IIIa inhibitors) in adult patients undergoing percutaneous coronary intervention (PCI). The primary outcomes comprised primary endpoint(death, MI or major bleeding), all-cause mortality(death), myocardial infarction (MI), stent thrombosis, revascularisation, significant bleeding and Stroke at 30 days. Two reviewers independently conducted study selection, data extraction, and risk of bias evaluation. The statistical analysis was conducted using the random or fixed effect model in Review Manager v5.3, and subgroup analyses were performed according to the publication year (before 2010 and after 2010), the type of STEMI, and whether Glycoprotein IIbIIIa was combined.The certainty of evidence was assessed with GRADE. Results: Bivalirudin significantly reduced the primary endpoint (OR 0.86, 95% CI 0.76–0.98, P < 0.00001, I 2 = 76%) and major bleeding (OR 0.60, 95% CI 0.46–0.79, P < 0.00001, I 2 = 83%). All-cause mortality (OR 0.92, 95% CI 0.80–1.05, P = 0.23), MI, stent thrombosis, revascularization, and stroke did not differ significantly. The bleeding advantage of the group receiving heparin combined with GPI was the most significant (OR 0.51, 95% CI 0.45–0.59), while this benefit in the heparin monotherapy group was less pronounced (P = 0.05). The post-2010 subgroup showed a diminished but persistent bleeding benefit (OR 0.61, 95% CI 0.42–0.87). Certainty of evidence was high for bleeding, moderate for the primary endpoint and death, and low for ischemic outcomes. Conclusion: In patients undergoing PCI, bivalirudin is associated with a significant reduction in the primary composite endpoint and major bleeding compared with heparin, but this finding is primarily driven by trials where heparin was combined with planned GPI. Against heparin monotherapy, the bleeding benefit is attenuated and not statistically robust. The bleeding benefit, though attenuated, persists in contemporary practice. All-cause mortality was not significantly reduced, and previous mortality claims should be interpreted cautiously. The choice of anticoagulant should be individualised based on bleeding risk, ischemic risk, access site, and bivalirudin infusion protocol. Clinical Trial Registration: PROSPERO (CRD420261289024).